Paper36769004
FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far?
Psilopatis I and 12 others. Int J Mol Sci, 2023. Cited by 23 papers, by iCite.
Cite this record
ConductScience Library. FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far? Papers, record 36769004. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36769004
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far?
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Hepatocellular | Major topic |
| Liver Neoplasms | Major topic |
| United States | |
| Humans | |
| Nivolumab | |
| United States Food and Drug Administration | |
| Antibodies, Monoclonal |
Source PubMed
References102
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28655991 | The impact of hepatitis C virus and human immunodeficiency virus coinfection on survival in patients with hepatocellular carcinoma. | Ann Gastroenterol | 2017 | https://conductscience.org/library/papers/28655991 | PubMed |
| 2 | 34094688 | Alpha-fetoprotein response at different time-points is associated with efficacy of nivolumab monotherapy for unresectable hepatocellular carcinoma. | Am J Cancer Res | 2021 | https://conductscience.org/library/papers/34094688 | PubMed |
| 3 | 34799975 | Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysis. | Hepatol Res | 2022 | https://conductscience.org/library/papers/34799975 | PubMed |
| 4 | 35884610 | Clinical Usefulness of Monitoring Muscle Volume during Atezolizumab Plus Bevacizumab Therapy in Patients with Unresectable Hepatocellular Carcinoma. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35884610 | PubMed |
| 5 | 34414118 | Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study. | Liver Cancer | 2021 | https://conductscience.org/library/papers/34414118 | PubMed |
| 6 | 18650514 | Sorafenib in advanced hepatocellular carcinoma. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18650514 | PubMed |
| 7 | 32007108 | Intensive care unit outcomes following orthotopic liver transplantation: single-center experience and review of the literature. | G Chir | 2019 | https://conductscience.org/library/papers/32007108 | PubMed |
| 8 | 32698317 | Monoclonal Antibodies in Cancer Therapy. | Antibodies (Basel) | 2020 | https://conductscience.org/library/papers/32698317 | PubMed |
| 9 | 30665869 | Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet Oncol | 2019 | https://conductscience.org/library/papers/30665869 | PubMed |
| 10 | 31940757 | Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/31940757 | PubMed |
| 11 | 35739268 | Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. | Nat Med | 2022 | https://conductscience.org/library/papers/35739268 | PubMed |
| 12 | 35877241 | Pretreatment Modified Albumin-Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma. | Curr Oncol | 2022 | https://conductscience.org/library/papers/35877241 | PubMed |
| 13 | 34761470 | Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis. | Hepatol Res | 2022 | https://conductscience.org/library/papers/34761470 | PubMed |
| 14 | 34114752 | Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience. | Cancer Rep (Hoboken) | 2022 | https://conductscience.org/library/papers/34114752 | PubMed |
| 15 | 34914889 | Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. | Lancet Oncol | 2022 | https://conductscience.org/library/papers/34914889 | PubMed |
| 16 | 34902530 | Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. | J Hepatol | 2022 | https://conductscience.org/library/papers/34902530 | PubMed |
| 17 | 36108891 | Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma. | Int J Radiat Oncol Biol Phys | 2023 | https://conductscience.org/library/papers/36108891 | PubMed |
| 18 | 33677453 | Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy. | Oncology | 2021 | https://conductscience.org/library/papers/33677453 | PubMed |
| 19 | 36368251 | Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis. | Eur J Cancer | 2022 | https://conductscience.org/library/papers/36368251 | PubMed |
| 20 | 28839428 | From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world. | World J Gastroenterol | 2017 | https://conductscience.org/library/papers/28839428 | PubMed |
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 23 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42491366 | Survival benefits of non-surgical triple therapy in hepatocellular carcinoma with inferior vena cava/right atrial tumor thrombus: A retrospective analysis from a multidisciplinary team. | Oncol Lett | 2026 | https://conductscience.org/library/papers/42491366 | PubMed |
| 42065059 | Navigating the Labyrinth of Hepatocellular Carcinoma: Leveraging AI/ML for Precision Oncology. | Oncol Res | 2026 | https://conductscience.org/library/papers/42065059 | PubMed |
| 41648957 | Cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) tumour expression in gastric carcinoma. | Indian J Med Res | 2025 | https://conductscience.org/library/papers/41648957 | PubMed |
| 41482353 | Augmenter of Liver Regeneration Enhances Hepatocellular Carcinoma Cell Growth Through COX-2-associated Signaling. | Cancer Genomics Proteomics | 2026 | https://conductscience.org/library/papers/41482353 | PubMed |
| 41461636 | Modeling hepatocellular carcinoma and its microenvironment on a chip. | Cell Death Discov | 2025 | https://conductscience.org/library/papers/41461636 | PubMed |
| 41108510 | Post-translational modifications in hepatocellular carcinoma: mechanisms and therapeutic potential. | Med Oncol | 2025 | https://conductscience.org/library/papers/41108510 | PubMed |
| 40741410 | Characterization of lactylation modification subtypes and the promoting role of CCL20 in hepatocellular carcinoma progression. | Front Genet | 2025 | https://conductscience.org/library/papers/40741410 | PubMed |
| 40686960 | Emerging Concepts in Immuno-Oncology: Insights from Natural Language Processing-Driven Co-Occurrence Analysis. | ACS Omega | 2025 | https://conductscience.org/library/papers/40686960 | PubMed |
| 40621467 | Antibody treatment of hepatocellular carcinoma: a review of current and emerging approaches. | Front Immunol | 2025 | https://conductscience.org/library/papers/40621467 | PubMed |
| 40071095 | Enhanced efficacy of immune checkpoint inhibitors combined locoregional therapy and tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma: A single - center retrospective study. | Front Oncol | 2025 | https://conductscience.org/library/papers/40071095 | PubMed |
| 39660127 | FOLFOX-HAIC combined with targeted immunotherapy for initially unresectable hepatocellular carcinoma: a real-world study. | Front Immunol | 2024 | https://conductscience.org/library/papers/39660127 | PubMed |
| 39412140 | Future investigative directions for novel therapeutic targets in head and neck cancer. | Expert Rev Anticancer Ther | 2024 | https://conductscience.org/library/papers/39412140 | PubMed |
| 39372389 | Clinical glycoproteomics: methods and diseases. | MedComm (2020) | 2024 | https://conductscience.org/library/papers/39372389 | PubMed |
| 39185414 | Progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma. | Front Immunol | 2024 | https://conductscience.org/library/papers/39185414 | PubMed |
| 38779103 | ULK1 Mediated Autophagy-Promoting Effects of Rutin-Loaded Chitosan Nanoparticles Contribute to the Activation of NF-κB Signaling Besides Inhibiting EMT in Hep3B Hepatoma Cells. | Int J Nanomedicine | 2024 | https://conductscience.org/library/papers/38779103 | PubMed |
| 38660476 | Synchronous Double Primary Tumors of Liver (Small Cell Neuroendocrine Carcinoma and Hepatocellular carcinoma): A Case Report. | Hepat Med | 2024 | https://conductscience.org/library/papers/38660476 | PubMed |
| 38069095 | Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/38069095 | PubMed |
| 38003674 | Emerging Role of Circular RNAs in Hepatocellular Carcinoma Immunotherapy. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/38003674 | PubMed |
Genes9
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AFP | 174 | PubTator's text mining | https://conductscience.org/library/genes/174 | NCBI Gene |
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| CTNNB1 | 1499 | PubTator's text mining | https://conductscience.org/library/genes/1499 | NCBI Gene |
| KDR | 3791 | PubTator's text mining | https://conductscience.org/library/genes/3791 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
| TGFB1 | 7040 | PubTator's text mining | https://conductscience.org/library/genes/7040 | NCBI Gene |
| TXK | 7294 | PubTator's text mining | https://conductscience.org/library/genes/7294 | NCBI Gene |
| VEGFA | 7422 | PubTator's text mining | https://conductscience.org/library/genes/7422 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36769004
GET https://conductscience.org/api/papers/v1/36769004/references?page=2